Ligand Pharmaceuticals (LGND) Net Income towards Common Stockholders (2010 - 2026)

Ligand Pharmaceuticals has disclosed Net Income towards Common Stockholders across 16 years of filings, most recently posting -$13.3 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$13.3 million, up 68.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $153.6 million (up 308.81% YoY), and the FY2025 annual result was $124.5 million, up 3186.63% from the prior year.
• Net Income towards Common Stockholders came in at -$13.3 million for Q1 2026 at Ligand Pharmaceuticals, down from $44.8 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $117.3 million in Q3 2025 to a low of -$42.5 million in Q1 2025.
• The 5-year median for Net Income towards Common Stockholders is -$3.0 million (2022), against an average of $4.6 million.
• Across the five-year window, Net Income towards Common Stockholders tumbled 136.03% in 2022 and surged 244.06% in 2025, its largest moves.
• Ligand Pharmaceuticals' Net Income towards Common Stockholders stood at -$3.0 million in 2022, then soared by 43.58% to -$1.7 million in 2023, then sank by 1767.15% to -$31.1 million in 2024, then soared by 244.06% to $44.8 million in 2025, then tumbled by 129.8% to -$13.3 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$13.3 million (Q1 2026), $44.8 million (Q4 2025), and $117.3 million (Q3 2025), per Business Quant data.